Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

» CVD's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2014

CVD Guru Trades in Q2 2014

Ken Fisher 25,621 sh (New)
Joel Greenblatt 356,011 sh (+2662.77%)
Paul Tudor Jones 15,836 sh (+116.93%)
Vanguard Health Care Fund 2,486,000 sh (+10.67%)
Ron Baron 300,000 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 701,680 sh (-3.32%)
Chuck Royce 293,000 sh (-9.29%)
Jim Simons 169,100 sh (-10.54%)
» More
Q3 2014

CVD Guru Trades in Q3 2014

Ray Dalio 6,437 sh (New)
Steven Cohen 139,500 sh (New)
Joel Greenblatt 650,283 sh (+82.66%)
Ken Fisher 39,027 sh (+52.32%)
Paul Tudor Jones 20,569 sh (+29.89%)
Vanguard Health Care Fund 2,486,000 sh (unchged)
Ron Baron 300,000 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 681,320 sh (-2.90%)
Jim Simons 120,500 sh (-28.74%)
Chuck Royce 146,500 sh (-50.00%)
» More
Q4 2014

CVD Guru Trades in Q4 2014

First Eagle Investment 20,000 sh (New)
Mario Gabelli 81,200 sh (New)
Jim Simons 427,900 sh (+255.10%)
Barrow, Hanley, Mewhinney & Strauss Sold Out
Steven Cohen Sold Out
Chuck Royce Sold Out
Ray Dalio Sold Out
Ron Baron Sold Out
Ken Fisher Sold Out
Vanguard Health Care Fund Sold Out
Joel Greenblatt 369,865 sh (-43.12%)
Paul Tudor Jones 6,819 sh (-66.85%)
» More
Q1 2015

CVD Guru Trades in Q1 2015

Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
First Eagle Investment Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CVD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Traded in other countries:CVD.Germany,

Covance, Inc is a Delaware Corporation, founded in 1987. The Company is a drug development services company providing early-stage and late-stage product development services mainly to the pharmaceutical, biotechnology and medical device industries. It also provides laboratory testing services to the chemical, agrochemical and food industries. Its two reportable segments are early development services, which include discovery support services, preclinical services and clinical pharmacology services; and late-stage development services, which include central laboratory, Phase II-IV clinical development, and market access services. The Company's preclinical services include toxicology services, pharmaceutical chemistry and related services. The Company's preclinical area has been a source of innovation by introducing new technologies for client access to data such as StudyTracker, electronic animal identification, multimedia study reports and animal and test tube measures of induced cell proliferation or reproduction. The Company's preclinical toxicology services include in vivo toxicology studies, which are studies of the effects of drugs in animals, genetic toxicology studies, which include studies of the effects of drugs on chromosomes, as well as on genetically modified mice and other specialized toxicology services. In its pharmaceutical chemistry services, it determines the metabolic profile and bioavailability of drug candidates. It also provides laboratory testing services to the chemical, agricultural chemical and food industries. The Company offers services to agricultural chemical manufacturers to determine the potential risk to humans, animals and the environment from plant protection products such as pesticides. In its nutritional chemistry services, the Company offers a range of services to the food, nutriceutical and animal feed industries, including nutritional analysis and equivalency, nutritional content fact labels, microbiological and chemical contaminant safety analysis, pesticide screening and stability testing. It provides custom polyclonal and monoclonal antibody services for research purposes and purpose-bred animals for biomedical research. The Company provides optimization and translational services including custom immunology and monoclonal antibody services, metabolism studies and pharmacokinetic screening as well as non-GLP toxicology, in vivo pharmacology, imaging services and biomarker services. The Company's bioanalytical testing services helps determine the appropriate dose and frequency of drug application from late discovery evaluation through Phase III clinical testing on a full-scale, globally integrated basis. The Company provides clinical pharmacology services, including first-in-human trials, of new pharmaceuticals at its seven clinics located throughout the United States and its one clinic in Leeds, United Kingdom. The Company offers reimbursement and healthcare economics consulting services

Guru Investment Theses on Covance Inc

Vanguard Health Care Fund Comments on Covance Inc - Mar 27, 2015

We eliminated our position in Covance (CVD), a contract research organization that works with biopharmaceutical companies to help manage their clinical trial process, after LabCorp announced in the fall that it would acquire the company.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $2,694
EPS (TTM) $ 3.13
Short Percentage of Float2.62%
52-Week Range $73.57 - 107.35
Shares Outstanding (Mil)56.58

Analyst Estimate

Dec14 Dec15 Dec16
Revenue (Mil $) 2,602 2,768 2,858
EPS ($) 3.85 4.38 4.62
EPS w/o NRI ($) 3.85 4.38 4.62
EPS Growth Rate
(3Y to 5Y Estimate)
Dividends Per Share ($)
» More Articles for CVD


Articles On GuruFocus.com
Mario Gabelli's Top 5 Stock Picks Mar 30 2015 
Vanguard Health Care Fund Comments on Covance Inc Mar 27 2015 
Laboratory Corporation of America Holdings Q4 Earnings Beat Market Expectations Feb 24 2015 
Mario Gabelli's Top 5 New Stock Buys of Q4 Feb 05 2015 
Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
Parexcel: Great Growth but a Tough Business Aug 17 2011 
Covance Inc. Reports Operating Results (10-K) Feb 28 2011 
Covance Inc. (CVD) Executive Vice President & COO Wendel Barr sells 13,000 Shares Dec 21 2010 
Covance Inc. (CVD) Executive Vice President & COO Wendel Barr sells 31,300 Shares Dec 15 2010 
Covance Inc. (CVD) Executive Vice President & COO Wendel Barr sells 19,305 Shares Nov 22 2010 

More From Other Websites
Covance Receives Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award Three Years... Oct 12 2016
LabCorp Names Veteran Biopharma Executive John Ratliff CEO of Covance Drug Development Sep 20 2016
LabCorp Q2 Results Strong, Sequenom Buyout Raises Hope Aug 19 2016
LabCorp (LH) Tops Q2 Earnings, View Up, to Buy Sequenom Jul 27 2016
[$$] Laboratory Corp Revenue and Profit Rise Jul 27 2016
LabCorp Sees Balanced Growth; Covance Synergy on Track Jun 21 2016
LabCorp (LH) Stock Price Target Boosted at Credit Suisse Jun 09 2016
Laboratory Corp. of America Looks Pretty Healthy Jun 02 2016
LabCorp (LH) Posts Strong Q1; Covance Synergy Continues May 17 2016
Early Development, Central Labs Businesses: Strong Demand in 1Q16 May 08 2016
Covance Drug Development Drives LabCorp’s 1Q16 Revenue Growth Apr 29 2016
Rumors Of Deal Put INC Research In The Spotlight Apr 27 2016
LabCorp (LH) Tops Q1 Earnings and Sales, Raises Guidance Apr 25 2016
Testing LabCorp's Deal Plans Apr 19 2016
LabCorp Hires Jonathan Zung as Group President of Clinical Development and Commercialization... Apr 11 2016
LabCorp (LH): Revenues Strong on Balanced Organic Growth Feb 23 2016
LabCorp Q4 Earnings Miss, Revenues Top; Currency Bothers Feb 18 2016
LabCorp Tops Revenues, Misses on Earnings in Q4 Feb 18 2016
Will LabCorp (LH) Disappoint Earnings Estimates in Q4? Feb 15 2016
LabCorp Poised on Strategic Initiatives, Currency Woes Linger Jan 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)